Issue link: https://www.e-digitaleditions.com/i/1462272
www.biopharminternational.com Quality and Regulatory Sourcebook eBook March 2022 BioPharm International 33 Supply Chain Considerations for Ensuring Quality Disruptions in the bio/pharmaceutical supply chain can have serious impacts on the quality and availability of life-saving medicines. D isruptions in the bio/pharmaceutical supply chain that impact capacity and capabilities result in longer lead times for drug prod- ucts, according to Ari Ojinaka, production manager at Astrea Bioseparations. The past two years of the COV ID-19pandemic have highlighted the importance of a healthy supply chain. "Through the pandemic, we have witnessed a signif icant reduction in inter-countr y transportation of goods and ser vices and in-country COVID-19 restriction impacting capacity and capabilities to manufacture," says Ojinaka. BioPharm International spoke with Ojinaka as well as Steve Kirk, vice-president Global Procurement, Catalent; Vincent Colicchio, v ice-president, Supply Chain and E x ter na l Ma nu fac t u r ing, Dr. Reddy 's Laborator ies; and Hami lton Lenox, senior v ice president–Business Development & Operations at LGM Pharma about the impact of COVID-19 on the supply chain and what com- panies can do to ensure the quality of their products. THE CONSEQUENCES OF SUPPLY CHAIN INTERRUPTIONS BioPharm: How can supply chain interruptions impact pharmaceutical manufacturing and drug availability? Colicchio (Dr. Reddy's Laboratories): Generally speaking, supply chain interruptions are one of the big- gest issues the pharma industry faces at this time. The main stress points are transportation and labor availability. COV ID has reduced the cargo capacity globally for all modes of transportation, which in turn has created a dom- ino effect for many of the other functions within the supply chain industry. With reduced transportation capacity, drug SUSAN HAIGNEY Quality and Regulatory Sourcebook Regulations: Supply Chain WrightStudio - Stock.adobe.com